Infinity's Hedgehog Pathway Inhibitor IPI-926 Demonstrates Significant Tumor Growth Inhibition In Human Pancreatic Cancer Model

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

Infinity Pharmaceuticals, Inc. today announced that preclinical studies of IPI-926, Infinity's oral Hedgehog pathway inhibitor currently in Phase 1 clinical development, demonstrate that the compound significantly down-regulates Hedgehog signaling in tumor stroma, thereby disrupting the communication process between tumor and stroma, ultimately leading to tumor growth inhibition.

 

0 Comments

You must be logged in to post comments.

We care about your feedback. Let us know how we can improve your CancerCompass experience.